Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers

Serum potassium and creatinine monitoring is recommended for patients prescribed angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). Much has been written about hyperkalemia associated with these drugs; little is known about laboratory monitoring patterns. The purpose of this retrospective cohort study was to assess creatinine and potassium monitoring and characteristics associated with monitoring among patients dispensed ACEi or ARB.

[1]  P. Palevsky,et al.  Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. , 1998, Archives of internal medicine.

[2]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[3]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[4]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[5]  Gregory E. Simon,et al.  A Chronic Disease Score with Empirically Derived Weights , 1995, Medical care.

[6]  J. Mahnken,et al.  Predictors of the Development of Hyperkalemia in Patients Using Angiotensin-Converting Enzyme Inhibitors , 2000, American Journal of Nephrology.

[7]  J. Avorn,et al.  Quality Indicators for Appropriate Medication Use in Vulnerable Elders , 2001, Annals of Internal Medicine.

[8]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[9]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[10]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[11]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[12]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[13]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[14]  Margaret J. Gunter,et al.  Brief report: Laboratory safety monitoring of chronic medications in ambulatory care settings , 2005, Journal of General Internal Medicine.

[15]  B. Palmer.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[18]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. , 2004, Seminars in nephrology.

[19]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[20]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[21]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[22]  Robert L Davis,et al.  Baseline Laboratory Monitoring of Cardiovascular Medications in Elderly Health Maintenance Organization Enrollees , 2005, Journal of the American Geriatrics Society.

[23]  M. Perazella,et al.  Drug-induced hyperkalemia: old culprits and new offenders. , 2000, The American journal of medicine.

[24]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[25]  M. Packer,et al.  Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. , 1999, The American journal of cardiology.

[26]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[27]  M B Weiss,et al.  Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.

[28]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[29]  R. Vanholder,et al.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. , 2001, American Journal of Medicine.

[30]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[31]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[32]  D. Macpherson,et al.  Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? , 1998, Archives of internal medicine.

[33]  F. Gennari,et al.  Hyperkalemia as a complication of drug therapy. , 1987, Archives of internal medicine.

[34]  J. McMurray,et al.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. , 2001, The American journal of medicine.

[35]  L. Doolan,et al.  Hyperkalemia and myocardial atonia following cardioselective β-blockade , 1993 .